ERBB2 and non-small cell lung carcinoma: In consideration of the complex evaluation of the overall risk-benefit analysis, the FDA has determined that additional data from a randomised controlled trial are needed before poziotinib can be approved in pre-treated patients with NSCLC harboring HER2 exon 20 insertion mutations.